MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
August 01 2023 - 6:00AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products and devices for patients with endocrine and
orphan lung diseases, announced today that its Chief Executive
Officer, Michael Castagna, PharmD, will participate in one-on-one
meetings at the 2023 Wedbush PacGrow Healthcare Conference on
Tuesday, August 8, 2023 at the Lotte Palace in New York City.
If you have interest in participating in the 2023 Wedbush
PacGrow Healthcare Conference, please reach out to your Wedbush
representative.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development
and commercialization of innovative therapeutic products and
devices to address serious unmet medical needs for those living
with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and
device engineering prowess to lessen the burden of diseases such as
diabetes, pulmonary arterial hypertension (PAH) and nontuberculous
mycobacterial (NTM) lung disease. Our signature technologies –
dry-powder formulations and inhalation devices – offer rapid and
convenient delivery of medicines to the deep lung where they can
exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide,
we are on a mission to give people control of their health and the
freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on
LinkedIn, Facebook, Twitter or Instagram.
MannKind Contact:Rose Alinaya,
Investor Relations(818) 661-5000Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024